Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

1900.00

Share Price

1752.78

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 75.51%
Worldwide Healthcare (Ordinary Share) NAV 78.74%
FTSE World 28.86%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 1795.0 -5.5% 1900.00 1909.00
27 Apr
107% 0.70%

Discrete performance % over

Fund / BenchmarkMay '13
Apr '14
May '14
Apr '15
May '15
Apr '16
Worldwide Healthcare (Ordinary Share) Price20.3354.49-5.58
Worldwide Healthcare (Ordinary Share) NAV18.2957.60-4.12
FTSE World7.2620.57-0.36

Discrete performance over

Discrete Performance

Top 10 Holdings

ONO Pharmaceutical Co., Ltd. 5.47%
Allergan, Inc. 5.47%
HCA Holdings Inc 5.06%
Bristol-Myers Squibb Company 4.25%
AbbVie Inc 4.15%
Amgen Inc 3.54%
Boston Scientific, Inc. 3.34%
Intuitive Surgical, Inc. 3.24%
Regeneron Pharmaceuticals, Inc. 2.94%
Biogen Idec Inc., 2.73%

Sectors weighting

Pharmaceuticals 98.80%
Net Current Assets 1.20%

Regional weighting

North America Region 63.00%
Europe Developed ex-UK 17.00%
Japan 10.00%
Asia exc Japan 6.00%
Other Countries 3.00%
Cash/Cash Equivalent 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 1752.78
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 48
  • Market Capital (£M) 850.69
  • Gross Assets (£M) 966.26
  • Net Assets (£M) 900.81
  • TER (%) 0.96
  • Historic Dividend Yield (%) 0.70
  • Last AGM 24 Sep 2015
  • Next AGM 24 Sep 2016
  • Last Annual Report Date 16 Jun 2014
  • Next due Report Date 31 Mar 2015
  • Next due Report Type A/R
  • Objective:

  • To invest worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Samuel. D Isaly Start: 28 Apr 1995
  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a.. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.